Advertisement
Organisation › Details
Ncardia (Group)
Ncardia develops, produces and commercializes highly predictive human cellular assay systems for safety and efficacy testing. The product portfolio encompasses a broad panel of hiPSC derived cryopreserved cardiomyocytes and neurons. In addition, the company delivers the CardioPlateTM product line of quality controlled ready to use assay plates. Using its cell products, Ncardia develops and provides its customers with a broad portfolio of cardiovascular services from safety pharmacology and disease modeling to cardiovascular drug efficacy screening. Ncardia is based in Belgium, The Netherlands, Germany, and the USA. The company is privately held and was established in September 2017 following the merger of Pluriomics and Axiogenesis, two well-known pioneers in the field of stem cell derived cells for safety and toxicology assessment. *
Start | 2017-09-18 merged | |
End | 2021-11-16 acq.controlstake | |
Group | Kiniciti Bio (WCAS invesment platform) (Group) | |
Today | Kiniciti Bio (WCAS invesment platform) (Group) | |
Predecessor | Axiogenesis AG | |
Successor | Kiniciti Bio (WCAS invesment platform) (Group) | |
Industry | iPSC technology (induced pluripotent stem cell technology) | |
Industry 2 | assay, research | |
Person | Fronhoff, Bernd (Axiogenesis 201603 CFO/COO) | |
Person 2 | Bohlen, Heribert (Axiogenesis 201603 CEO) | |
Region | Gosselies | |
Country | Belgium | |
Street | 47 Rue Adrienne Bolland | |
City | 6041 Gosselies | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | C: 51 to 100 (2017-09-18) |
* Document for »About Section«: Ncardia. (12/4/17). "Press Release: Ncardia and Evotec Entered a Licencing Agreement for Disease Modelling Using iPS Cells". Gosselies. | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Kiniciti Bio (WCAS invesment platform) (Group)
- [1] Quell Therapeutics Ltd.. (4/27/22). "Press Release: Quell Therapeutics and Cellistic Enter a Strategic Collaboration to Develop an iPSC-derived Allogeneic T-regulatory (Treg) Cell Therapy Platform". London & Gosselies....
- [2] Ncardia Services B.V.. (2/24/22). "Press Release: Ncardia Appoints Andy Holt as Chief Commercial Officer". Leiden....
- [3] Ncardia. (11/16/21). "Press Release: Ncardia Secures $60+ Million to Enhance and Expand Leading iPSC Offerings". Gosselies & New York, NY....
- [4] BlueRock Therapeutics LP. (1/21/20). "Press Release: Ncardia and BlueRock Therapeutics Announce Collaboration Agreement and Licensing of Process Development Technologies for the Manufacture of iPSC-derived Cardiomyocytes". Leiden & Cambridge, MA....
- [5] Ncardia. (12/4/17). "Press Release: Ncardia and Evotec Entered a Licencing Agreement for Disease Modelling Using iPS Cells". Gosselies....
- [6] Ncardia. (11/17/17). "Press Release: Ncardia Announces Completion of €10.5m Investment Round". Gosselies....
- [7] Ncardia. (9/18/17). "Press Release: Ncardia Established Following Pluriomics Axiogenesis Merger". Gosselies, Cologne, Leiden & Philadelphia, PA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top